May 24, 2021 / 02:00PM GMT
Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst
We have Amicus Therapeutics here with us today. With us from Amicus is John Crowley, Chairman and CEO. Thank you so much for joining us at the UBS Healthcare Conference.
Questions and Answers:
Eliana Rachel Merle - UBS Investment Bank, Research Division - AnalystAnd maybe just to kick it off, John, just for some background, those who are newer to the story. Can you give us a quick overview of Amicus' rare disease portfolio and, I guess, key goals for the company in the coming years?
John F. Crowley - Amicus Therapeutics, Inc. - Chairman & CEO
Great. Of course, Ellie. Thank you, and thank you for having me. I apologize I have to join by telephone here. I guess I didn't have the latest version of Google Chrome updated. But thank you, everybody, for listening.
To remind everybody, Amicus is a global biotechnology company, and we focus in the rare diseases, and we have since the founding of the company. We have a range of
Trustpilot
